Compare POET & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | MANE |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2008 | N/A |
| Metric | POET | MANE |
|---|---|---|
| Price | $8.08 | $96.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $83.33 |
| AVG Volume (30 Days) | ★ 28.5M | 550.5K |
| Earning Date | 05-13-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $848.96 | N/A |
| Revenue Next Year | $700.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.79 | $36.26 |
| 52 Week High | $15.50 | $101.81 |
| Indicator | POET | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 70.69 |
| Support Level | $5.40 | $54.23 |
| Resistance Level | $9.14 | N/A |
| Average True Range (ATR) | 1.37 | 8.17 |
| MACD | 0.20 | 1.87 |
| Stochastic Oscillator | 22.69 | 75.41 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.